Market Place
Sourcing Support
All News #Library
Biotech
IDMC Recommends Cohort 2 12 mg/kg In ELEVATE-44-201 Trial
17 Feb 2026 //
GLOBENEWSWIRE
Entrada Therapeutics Advances Rna-Based Therapeutics
08 Jan 2026 //
GLOBENEWSWIRE
Entrada Therapeutics Authorized for ELEVATE-45-201 Study in UK
24 Mar 2025 //
GLOBENEWSWIRE
Entrada`s 2-year ordeal ends as FDA lifts hold on DMD drug
25 Feb 2025 //
FIERCE BIOTECH
Entrada Gets FDA Nod To Lift Clinical Hold On ENTR-601-44
24 Feb 2025 //
GLOBENEWSWIRE
Entrada Therapeutics Receives UK Authorization for Duchenne Study
03 Feb 2025 //
GLOBENEWSWIRE
Entrada reports positive Phase 1 ENTR-601-44-101 Trial data for DMD.
24 Jun 2024 //
GLOBENEWSWIRE
Entrada Announces First Participant Dosed in its Phase 1 Trial of ENTR-601-44
21 Sep 2023 //
GLOBENEWSWIRE
Entrada Receives Authorization in UK to Initiate Phase 1 Trial of ENTR-601-44
01 Aug 2023 //
GLOBENEWSWIRE
Entrada Announces ENTR-601-45 for the Treatment of Duchenne Muscular Dystrophy
09 Jan 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.